(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 July 2014 (17.07.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/108198 A1

(51) International Patent Classification:
C07K 16/00 (2006.01) *C07K 16/36* (2006.01)
C07K 16/28 (2006.01) *A61K 39/395* (2006.01)

(21) International Application Number:
PCT/EP2013/050429

(22) International Filing Date:
10 January 2013 (10.01.2013)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant: **GENMAB B.V.** [NL/NL]; Yalelaan 60, NL-3584 CM Utrecht (NL).

(72) Inventors: **PARREN, Paul**; c/o Genmab B.V., Yalelaan 60, NL-3584 CM Utrecht (NL). **BEURSKENS, Frank**; c/o Genmab B.V., Yalelaan 60, NL-3584 CM Utrecht (NL). **DE JONG, Rob, N.**; c/o Genmab B.V., Yalelaan 60, NL-3584 CM Utrecht (NL). **VERPLOEGEN, Sandra**; c/o Genmab B.V., Yalelaan 60, NL-3584 CM Utrecht (NL). **LABRIJN, Aran, Frank**; c/o Genmab B.V., Yalelaan 60, NL-3584 CM Utrecht (NL). **SCHUURMAN, Janine**; c/o Genmab B.V., Yalelaan 60, NL-3584 CM Utrecht (NL).

(74) Agent: **GENMAB A/S**; Bredgade 34 E, DK-1260 Copenhagen K (DK).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: HUMAN IGG1 FC REGION VARIANTS AND USES THEREOF

(57) Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc: Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved complement-dependent cytotoxicity (CDC).

Figure 32B



WO 2014/108198 A1

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*